Zeneca launching Sular (nisoldipine) extended-release calcium channel blocker in January.
Executive Summary
ZENECA's SULAR (NISOLDIPINE) CCB WILL BE LAUNCHED IN JANUARY following a final agreement between Zeneca and Bayer AG giving Zeneca U.S. marketing and NDA rights to the once-daily calcium channel blocker. Zeneca is negotiating with Bayer for rights in other countries. Sular joins Zeneca's cardiovascular line of the ACE inhibitor Zestril (lisinopril), the ACE/diuretic combo Zestoretic, the beta-blocker Tenormin (atenolol), its diuretic combo Tenoretic and the nitrate Sorbitrate (isosorbide dinitrate).